Gene therapy for inborn errors of immunity: Current clinical progress.

Area of Science:

• Immunology
• Genetics
• Molecular Biology

Background:

• Hematopoietic stem cell transplant is a curative treatment for severe inborn errors of immunity (IEI).
• Histocompatibility differences between donor and patient pose risks for adverse outcomes in transplants.
• Gene therapy presents a novel strategy to address genetic defects in patients' cells.

Purpose of the Study:

• To review the development and application of gene therapy for inborn errors of immunity.
• To highlight advances in gene insertion and gene editing techniques for IEI treatment.
• To discuss the safety and efficacy of current gene therapy approaches in clinical trials.

Main Methods:

• Gene therapy approaches utilize gene insertion via retroviral vectors or gene editing with nucleases and DNA templates.
• Development of strategies to correct gene defects in patient cells.
• Clinical trials assessing safety and efficacy of gene therapy for various IEI.

Main Results:

• Successful gene therapy clinical trials for three forms of severe combined immunodeficiency have been achieved.
• Demonstrated safety and efficacy of gene therapy in treating specific IEI conditions.
• Ongoing preclinical and clinical studies for a range of other diverse IEI.

Conclusions:

• Gene therapy is a promising curative treatment for severe IEI, overcoming limitations of traditional transplantation.
• Advances in gene editing and vector technology have improved safety and efficacy.
• Gene therapy holds significant potential for treating a broad spectrum of inborn errors of immunity.